Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward ...

Zimmer Biomet has hired The Terminator to tell the world that “if you rest, you rust.” The manufacturer of orthopedic medtech ...

While personally “disappointed” about the election’s outcome, current FDA Commissioner Robert Califf, M.D., has laid out the ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to ...

In a bid to streamline viral vector manufacturing, Thermo Fisher is charting another round of layoffs this year—and ...

PhRMA is pushing to get pharmacy benefit manager (PBM) reform over the line in Congress’ lame-duck session, using its first ...

AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total ...